ATE466948T1 - Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle - Google Patents

Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle

Info

Publication number
ATE466948T1
ATE466948T1 AT98910289T AT98910289T ATE466948T1 AT E466948 T1 ATE466948 T1 AT E466948T1 AT 98910289 T AT98910289 T AT 98910289T AT 98910289 T AT98910289 T AT 98910289T AT E466948 T1 ATE466948 T1 AT E466948T1
Authority
AT
Austria
Prior art keywords
dna
cell
introducing
nucleic acid
transposon system
Prior art date
Application number
AT98910289T
Other languages
English (en)
Inventor
Perry Hackett
Zoltan Ivics
Zsuzsanna Izsvak
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Application granted granted Critical
Publication of ATE466948T1 publication Critical patent/ATE466948T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT98910289T 1997-03-11 1998-03-11 Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle ATE466948T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4066497P 1997-03-11 1997-03-11
US5386897P 1997-07-28 1997-07-28
US6530397P 1997-11-13 1997-11-13
PCT/US1998/004687 WO1998040510A1 (en) 1997-03-11 1998-03-11 Dna-based transposon system for the introduction of nucleic acid into dna of a cell

Publications (1)

Publication Number Publication Date
ATE466948T1 true ATE466948T1 (de) 2010-05-15

Family

ID=27365765

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98910289T ATE466948T1 (de) 1997-03-11 1998-03-11 Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle

Country Status (10)

Country Link
US (2) US6489458B2 (de)
EP (1) EP0973928B1 (de)
JP (2) JP2002511741A (de)
KR (1) KR20000076157A (de)
AT (1) ATE466948T1 (de)
AU (1) AU745049B2 (de)
CA (1) CA2280997C (de)
DE (1) DE69841648D1 (de)
DK (1) DK0973928T3 (de)
WO (1) WO1998040510A1 (de)

Families Citing this family (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0973928T3 (da) * 1997-03-11 2010-08-09 Univ Minnesota DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
WO1999025817A2 (en) * 1997-11-13 1999-05-27 Regents Of The University Of Minnesota Tc1-based transposon vectors
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
JP2004501601A (ja) * 1999-02-19 2004-01-22 アサーシス，インコーポレイテッド 標的化によらない内在性遺伝子の活性化組成物および活性化方法
US6299850B1 (en) 1999-03-16 2001-10-09 The United States Of America As Represented By The Department Of Energy Carbon activation process for increased surface accessibility in electrochemical capacitors
US6562624B2 (en) 1999-03-17 2003-05-13 Paradigm Genetics, Inc. Methods and materials for the rapid and high volume production of a gene knock-out library in an organism
JP2002543792A (ja) * 1999-05-11 2002-12-24 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ベクターによるトランスポゾン配列の供給及び組込み
US7196244B1 (en) * 1999-06-01 2007-03-27 University Of Utah Method of transposon-mediated mutagenesis in the nematode caenorhabditis elegans
AU1292301A (en) * 1999-10-19 2001-04-30 Minos Biosystems Limited Method for genetic manipulation
AU7900300A (en) * 1999-10-26 2001-05-08 Shanghai Bio Road Gene Development Ltd. A novel polypeptide - human pogo transposase 14 and a polynucleotide encoding the same
WO2001030965A2 (en) * 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
CN1300827A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽—人水手转座酶19和编码这种多肽的多核苷酸
JP2001231567A (ja) * 2000-02-18 2001-08-28 Inst Of Physical & Chemical Res テロメア長の調節方法
MXPA02008361A (es) * 2000-02-28 2004-05-17 Genesegues Inc Sistema y metodo de encapsulacion de nanocapsulas.
AU2001265756A1 (en) * 2000-04-27 2001-11-07 Max-Delbruck-Centrum Fur Molekulare Medizin Sleeping beauty, a transposon vector with a broad host range for the genetic transfprmation in vertebrates
WO2002086074A2 (en) * 2001-04-20 2002-10-31 Regents Of The University Of Minnesota Compositions for delivery of compounds to cells and methods of use
EP1308516A1 (de) * 2001-10-24 2003-05-07 ADEREGEM (Association pour le Développement de la Recherche en Génétique Moléculaire Zielgerichtete Rekombinase-Fusionsproteine und entsprechende Polynukleotide, Vektoren und Kits, und deren Verwendungen zur zielgerichteten DNS-Rekombination
WO2003089618A2 (en) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
US7164056B2 (en) 2002-05-03 2007-01-16 Pioneer Hi-Bred International, Inc. Gene targeting using replicating DNA molecules
DE10224242A1 (de) * 2002-05-29 2003-12-11 Max Delbrueck Centrum Frog Prince, ein Transposonvektor für den Gentransfer bei Wirbeltieren
US7527966B2 (en) * 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
US20040172667A1 (en) * 2002-06-26 2004-09-02 Cooper Richard K. Administration of transposon-based vectors to reproductive organs
EP1380289A1 (de) * 2002-07-10 2004-01-14 Denis Bron Verabreichungsform für pharmazeutische Agenzien
TW200411052A (en) * 2002-07-12 2004-07-01 Takara Bio Inc Method of transferring mutation into target nucleic acid
ATE498016T1 (de) * 2003-02-10 2011-02-15 Max Delbrueck Centrum Transposon-system zur gezielten integration
US8420386B2 (en) * 2003-02-10 2013-04-16 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Transposon-based targeting system
US20060236413A1 (en) * 2003-02-10 2006-10-19 Zoltan Ivics Transposon-based targeting system
US7985739B2 (en) * 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
WO2005003359A1 (ja) * 2003-07-08 2005-01-13 Japan Science And Technology Corporation トランスジェニック生物を作製する方法およびシステム
US7194978B2 (en) * 2003-08-22 2007-03-27 University Of Maryland Biotechnology Institute Inducing sterility in fish by disrupting the development of the GnRH system
US8071364B2 (en) * 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
WO2005100585A2 (en) 2004-03-30 2005-10-27 Epicentre Methods for obtaining directionally truncated polypeptides
US20060294606A1 (en) * 2004-05-18 2006-12-28 Istefo Moisyadi Tn5 transposase-mediated transgenesis
US20060026699A1 (en) * 2004-06-04 2006-02-02 Largaespada David A Methods and compositions for identification of genomic sequences
CA2585098C (en) 2004-10-22 2018-12-18 Revivicor, Inc. Porcine genomic kappa and lambda light chain sequences
US7919583B2 (en) * 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
US9228180B2 (en) 2007-07-04 2016-01-05 Max-Delbruck-Centrum Fur Molekulare Medizin Polypeptide variants of sleeping beauty transposase
DE102007048134A1 (de) * 2007-10-05 2009-04-09 Evocatal Gmbh Verfahren und Gen-Kassetten zur Klonierung, Integration und Expression mehrerer Gene eines Genclusters
CA2621155A1 (en) * 2008-02-29 2009-08-29 James Ellis Stem cell expression cassettes
WO2010008564A2 (en) * 2008-07-16 2010-01-21 Recombinetics Plaice dna transposon system
WO2010036976A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of antibodies
WO2010036978A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of growth hormone
EP2342224A2 (de) * 2008-09-25 2011-07-13 TransGenRx, Inc. Neue vektoren zur herstellung von interferon
DK2348827T3 (en) 2008-10-27 2015-07-20 Revivicor Inc IMMUNICIPLY COMPROMATED PETS
CA2750027C (en) 2009-01-23 2020-11-10 Nsgene A/S Improved cell lines and their use in encapsulated cell biodelivery
WO2010083842A2 (en) 2009-01-23 2010-07-29 Nsgene A/S Expression of neuropeptides in mammalian cells
EP2417263B1 (de) * 2009-04-09 2015-09-23 ProteoVec Holding L.L.C. Herstellung von proteinen unter verwendung von vektoren auf transposonbasis
US8722964B2 (en) * 2009-04-23 2014-05-13 Transposagen Biopharmaceuticals, Inc. Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes
EP2449112A1 (de) 2009-07-01 2012-05-09 Transposagen Biopharmaceuticals, Inc. Genetisch modifizierte rattenmodelle für schwere kombinierte immundefizienz (scid)
US8502015B1 (en) 2009-07-06 2013-08-06 Transgenex Nanobiotech, Inc. Method of inducing cancer
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
US8558055B2 (en) 2009-07-24 2013-10-15 Transposagen Biopharmaceuticals, Inc. Genetically modified rat comprising a cytokine gene disruption and exhibiting a greater susceptibility to a cytokine-mediated autoimmune and/or inflammatory disease
WO2011014721A2 (en) 2009-07-30 2011-02-03 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for pharmacokinetics
NZ598457A (en) * 2009-08-03 2014-06-27 Recombinetics Inc Methods and compositions for targeted gene modification
EP2461672A2 (de) * 2009-08-05 2012-06-13 Transposagen Biopharmaceuticals, Inc. Genetisch modifizierte rattenmodelle für arzneimittelstoffwechsel
WO2011022634A2 (en) 2009-08-20 2011-02-24 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for pain
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
WO2011153440A2 (en) 2010-06-04 2011-12-08 Regents Of The University Of Minnesota Transposon mutagenesis system and methods of use
RU2447150C1 (ru) * 2010-11-26 2012-04-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН Средство для генной терапии злокачественных опухолей
WO2012129198A1 (en) 2011-03-23 2012-09-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for obesity and diabetes
PT2692865E (pt) 2012-07-30 2015-02-06 Nbe Therapeutics Llc Identificação mediada por transposição de proteínas funcionais ou de ligação específicas
EP2997134B1 (de) 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Menschliche anwendung manipulierter chimärer antigen-rezeptor (car)-t-zellen
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
DK3105335T3 (da) 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
SG10201902499VA (en) 2014-09-03 2019-04-29 Genesegues Inc Therapeutic nanoparticles and related compositions, methods and systems
CA2964783C (en) 2014-11-05 2024-01-23 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
CA2964785A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
EP3234130B1 (de) 2014-12-19 2020-11-25 The Broad Institute, Inc. Verfahren zum profiling vom t-zell-rezeptor-repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
JP6775515B2 (ja) 2015-03-11 2020-10-28 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム トランスポザーゼポリペプチド及びその使用
JP6913032B2 (ja) 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
AU2016279062A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075147A1 (en) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
GB201602473D0 (en) 2016-02-11 2016-03-30 Horizon Discovery Ltd Replicative transposon system
EP3219803A1 (de) 2016-03-15 2017-09-20 Max-Delbrück-Centrum für Molekulare Medizin Verbesserte dornröschen-transposone, kits und verfahren für die transposition
WO2020047527A2 (en) 2018-09-02 2020-03-05 F1 Bioventures, Llc Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
WO2018161064A1 (en) 2017-03-03 2018-09-07 F1 Oncology, Inc. Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
US12048718B2 (en) 2016-06-07 2024-07-30 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
CN118652336A (zh) 2016-06-08 2024-09-17 普瑞赛格恩公司 Cd33特异性嵌合抗原受体
US11630103B2 (en) 2016-08-17 2023-04-18 The Broad Institute, Inc. Product and methods useful for modulating and evaluating immune responses
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
US12499971B2 (en) 2016-09-28 2025-12-16 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
CA3049652A1 (en) 2017-01-10 2018-07-19 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
EP3574116A1 (de) 2017-01-24 2019-12-04 The Broad Institute, Inc. Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids
CN110809716B (zh) 2017-02-12 2023-07-07 百欧恩泰美国公司 基于hla的方法和组合物及其用途
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
EP3606518A4 (de) 2017-04-01 2021-04-07 The Broad Institute, Inc. Verfahren und zusammensetzungen zur detektion und zur modulation einer immuntherapieresistenzgensignatur in krebs
US12590288B2 (en) 2017-04-12 2026-03-31 The Broad Institute, Inc. Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
US20210293783A1 (en) 2017-04-18 2021-09-23 The General Hospital Corporation Compositions for detecting secretion and methods of use
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
EP3625342B1 (de) 2017-05-18 2022-08-24 The Broad Institute, Inc. Systeme, verfahren und zusammensetzungen zur gezielten nukleinsäureeditierung
EP3635132A4 (de) 2017-06-07 2021-05-26 Intrexon Corporation Expression von neuartigen zellmarkern
EP3638218A4 (de) 2017-06-14 2021-06-09 The Broad Institute, Inc. Zusammensetzungen und verfahren zum targeting von komplementierender komponente 3 zur hemmung des tumorwachstums
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
EP4549554A3 (de) 2017-07-29 2025-08-06 Juno Therapeutics, Inc. Reagenzien zur expansion von zellen, die rekombinante rezeptoren exprimieren
CA3072859A1 (en) 2017-08-23 2019-02-28 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinscht Chimeric antigen receptor and car-t cells that bind cxcr5
KR102338449B1 (ko) 2017-09-21 2021-12-10 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
US11732257B2 (en) 2017-10-23 2023-08-22 Massachusetts Institute Of Technology Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
CA3080509A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for producing a t cell composition
JP7357626B2 (ja) 2017-11-01 2023-10-06 ジュノー セラピューティクス インコーポレイテッド 操作された細胞の治療用組成物を生成するためのプロセス
US12171783B2 (en) 2017-11-13 2024-12-24 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
JP7557367B2 (ja) 2017-11-17 2024-09-27 アイオバンス バイオセラピューティクス，インコーポレイテッド 細針吸引及び小生検からのｔｉｌ拡大培養
JP2021503885A (ja) 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
EP3737743A1 (de) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Verfahren zur erzeugung von til-produkten, die für tumorantigenspezifische t-zellen angereichert sind
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
SG11202008539YA (en) 2018-03-06 2020-10-29 Precigen Inc Human papillomavirus vaccines and uses of the same
CN112189018A (zh) 2018-04-20 2021-01-05 汉诺威医学院 结合疱疹病毒抗原的嵌合抗原受体和car-t细胞
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019210131A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2020041384A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
US12391685B2 (en) 2018-08-20 2025-08-19 The Broad Institute, Inc. Inhibitors of RNA-guided nuclease target binding and uses thereof
WO2020041387A1 (en) 2018-08-20 2020-02-27 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
IL282775B1 (en) 2018-11-05 2026-05-01 Iovance Biotherapeutics Inc Selection of enhanced carrier-reactive T cells
US12453697B2 (en) 2018-11-05 2025-10-28 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
BR112021008549A2 (pt) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020131547A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
CA3124457A1 (en) 2018-12-21 2020-06-25 Biontech Us Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
SG11202109331QA (en) 2019-03-01 2021-09-29 Iovance Biotherapeutics Inc Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (de) 2019-03-18 2022-01-26 The Broad Institute, Inc. Zusammensetzungen und verfahren zur modulation metabolischer regulatoren der t-zell-pathogenität
AU2020247119A1 (en) 2019-03-25 2021-09-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Enhancement of cytolytic T-cell activity by inhibiting EBAG9
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
JP7702884B2 (ja) 2019-06-05 2025-07-04 ドイチェス ツェントラム フューア ノイロデジェネラティヴ エアクランクンゲン エー． ファウ．（ディーゼットエヌイー） 神経学的自己免疫疾患における中枢神経系を標的とする自己抗体に結合するキメラ自己抗体受容体（ｃａａｒ）
BR112021026832A2 (pt) 2019-07-02 2022-05-10 Hutchinson Fred Cancer Res Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
EP4048295A1 (de) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Genbearbeitung von tumorinfiltrierenden lymphozyten und deren verwendungen in der immuntherapie
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US20220412954A1 (en) 2019-11-05 2022-12-29 Juno Therapeutics, Inc. Methods of determining attributes of therapeutic t cell compositions
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
US12516291B2 (en) 2019-12-11 2026-01-06 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス，アイエヌシー． がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
CN113584083A (zh) 2020-04-30 2021-11-02 深圳市深研生物科技有限公司 用于逆转录病毒载体的生产细胞和包装细胞及其制备方法
WO2021226061A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4146793A1 (de) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Auswahl von verbesserten tumorreaktiven t-zellen
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
WO2021260696A1 (en) 2020-06-22 2021-12-30 Ramot At Tel-Aviv University Ltd. Multi subunit protein modules, cells expressing same and uses thereof
AU2021334950A1 (en) 2020-08-24 2023-03-02 Charité - Universitätsmedizin Berlin Chimeric antigen receptor (CAR)-expressing cells recognizing CEA
US20240009310A1 (en) 2020-08-24 2024-01-11 Charité - Universitätsmedizin Berlin A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6
CA3195019A1 (en) 2020-10-06 2022-04-14 Maria Fardis Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2024501452A (ja) 2020-12-11 2024-01-12 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｂｒａｆ阻害剤及び／またはｍｅｋ阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療
JP2023554395A (ja) 2020-12-17 2023-12-27 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｔｌａ－４及びｐｄ－１阻害剤と併用した腫瘍浸潤リンパ球療法による治療
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
US20240041927A1 (en) 2020-12-22 2024-02-08 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Chimeric autoantibody receptor (caar) comprising a nicotinic acetylcholine receptor autoantigen
EP4019538A1 (de) 2020-12-22 2022-06-29 Charité - Universitätsmedizin Berlin Umprogrammierung von immunzellen durch gezielte integration von zeta-defizitären chimären antigen-rezeptor-transgenen
CA3203531A1 (en) 2020-12-30 2022-07-07 Simon Olivares Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2022155500A1 (en) 2021-01-14 2022-07-21 Senti Biosciences, Inc. Secretable payload regulation
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
AU2022229358A1 (en) 2021-03-01 2023-09-07 Exuma Biotech Corp. Methods and compositions for the delivery of retroviral particles
TW202304480A (zh) 2021-03-19 2023-02-01 美商艾歐凡斯生物治療公司 腫瘤浸潤淋巴球（ｔｉｌ）中之與ｃｄ３９／ｃｄ６９選擇及基因剔除相關之ｔｉｌ擴增之方法
US20240168012A1 (en) 2021-03-22 2024-05-23 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
EP4314253A2 (de) 2021-03-25 2024-02-07 Iovance Biotherapeutics, Inc. Verfahren und zusammensetzungen für t-zell-kokulturpotenztests und verwendung mit zelltherapieprodukten
AU2022263418A1 (en) 2021-04-19 2023-10-26 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
US20240269180A1 (en) 2021-05-17 2024-08-15 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
CA3226111A1 (en) 2021-07-22 2023-01-26 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
CA3226942A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
CA3231018A1 (en) 2021-09-09 2023-03-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
US20230187042A1 (en) 2021-10-27 2023-06-15 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
AU2022388729A1 (en) 2021-11-10 2024-05-16 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
GB202117314D0 (en) 2021-11-30 2022-01-12 Clarke David John Cyclic nucleic acid fragmentation
WO2023122716A1 (en) 2021-12-22 2023-06-29 Vanderbilt University Next generation transpososomes
EP4469065A1 (de) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Zusammensetzungen und verfahren für cytokinassoziierte tumorinfiltrierende lymphozyten
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
US20250230412A1 (en) 2022-02-01 2025-07-17 President And Fellows Of Harvard College Methods and compositions for treating cancer
EP4476331A2 (de) 2022-02-07 2024-12-18 Ensoma, Inc. Inhibitorresistente mgmt-modifikationen und modifikation mgmt-codierender nukleinsäuren
US20250099612A1 (en) 2022-03-01 2025-03-27 Exuma Biotech Corp. Viral particles with membrane-bound hyaluronidase
WO2023173137A1 (en) 2022-03-11 2023-09-14 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
WO2023183344A1 (en) 2022-03-21 2023-09-28 Alaunos Therapeutics, Inc. Methods for identifying neoantigen-reactive t cell receptors
JP2025512313A (ja) 2022-04-06 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
EP4507704A1 (de) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til-expansionsverfahren unter verwendung spezifischer zytokinkombinationen und/oder einer akti-behandlung
EP4522202A1 (de) 2022-05-10 2025-03-19 Iovance Biotherapeutics, Inc. Behandlung von krebspatienten mit tumorinfiltrierenden lymphozytentherapien in kombination mit einem il-15r-agonisten
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
AU2023275671A1 (en) 2022-05-27 2024-11-14 Kite Pharma, Inc. Non-viral delivery of cell therapy constructs
EP4565683A1 (de) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimäre kostimulatorische rezeptoren, chemokinrezeptoren und deren verwendung in zellulären immuntherapien
CN116949092A (zh) * 2022-09-21 2023-10-27 上海吉量医药工程有限公司 一种转座子系统及其应用
EP4598949A1 (de) 2022-10-07 2025-08-13 The General Hospital Corporation Verfahren und zusammensetzungen zur hochdurchsatzentdeckung von auf peptid-mhc abzielenden bindungsproteinen
EP4353253A1 (de) 2022-10-10 2024-04-17 Charité - Universitätsmedizin Berlin Reinigung von tcr-modifizierten t-zellen unter verwendung tcr-spezifischer car-nk-zellen
EP4612277A1 (de) 2022-11-04 2025-09-10 Iovance Biotherapeutics, Inc. Verfahren zur expansion von tumorinfiltrierenden lymphozyten (til) im zusammenhang mit cd39/cd103-auswahl
US20260124242A1 (en) 2022-11-04 2026-05-07 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
CN120548323A (zh) 2022-11-18 2025-08-26 首尔国立大学校产学协力团 利用ctla-4变体及嵌合抗原受体的双基因转导免疫细胞及其用途
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024112711A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Methods for assessing proliferation potency of gene-edited t cells
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024154122A1 (en) 2023-01-18 2024-07-25 Gilboa Therapeutics LTD Immune cells expressing a complement receptor and uses thereof
WO2024197072A2 (en) 2023-03-21 2024-09-26 Alaunos Therapeutics, Inc. Identification of neoantigen-reactive t cell receptors
KR20250169631A (ko) 2023-04-18 2025-12-03 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
EP4716851A2 (de) 2023-05-23 2026-04-01 Juno Therapeutics, Inc. Aktivierungsmarker von t-zellen und verfahren zur beurteilung der t-zellaktivierung
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025096916A1 (en) 2023-11-03 2025-05-08 The Broad Institute, Inc. Multi-site editing in living cells
IL328125A (en) 2023-11-06 2026-06-01 Iovance Biotherapeutics Inc Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
AU2024394385A1 (en) 2023-12-07 2026-06-11 T-Curx Gmbh Method of producing leukocytes expressing artificial antigen receptors
WO2025158420A1 (en) 2024-01-25 2025-07-31 Nanocell Therapeutics Holdings B.V. Methods and composition for inducing activation and dna expression in t-cells
WO2025169168A1 (en) 2024-02-09 2025-08-14 Nanocell Therapeutics Holdings B.V. Extracorporeal transfection of immune effector cells
WO2025176860A1 (en) 2024-02-23 2025-08-28 Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts Dual chimeric antigen receptor construct targeting cea and epcam
WO2026050217A2 (en) 2024-08-27 2026-03-05 Iovance Biotherapeutics, Inc. Engineered artificial antigen presenting cells and lipid nanoparticles for tumor infiltrating lymphocyte expansion
WO2026073244A1 (en) 2024-09-30 2026-04-02 Ensoma, Inc. Constructs for multi-lineage expression of therapeutic agents
WO2026125719A1 (en) 2024-12-13 2026-06-18 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Caspr2 chimeric autoantibody receptor
WO2026159700A1 (en) 2025-01-27 2026-07-30 Nanocell Therapeutics Holdings B.V. Methods and composition for inducing activation and dna expression in t-cells

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631259A (en) 1983-05-04 1986-12-23 Board Of Regents Of The University Of Michigan Transposon in cloning DNA
WO1988001646A1 (en) 1986-08-26 1988-03-10 Allelix Inc. Universal system for transposon mutagenesis
FR2627508B1 (fr) * 1988-02-22 1990-10-05 Eurolysine Procede pour l'integration d'un gene choisi sur le chromosome d'une bacterie et bacterie obtenue par ledit procede
EP0485701A1 (de) 1990-09-28 1992-05-20 American Cyanamid Company Einfügen von DNS mittels abgewandelter Transposons
ES2121794T3 (es) 1990-10-25 1998-12-16 Clague Pitman Hodgson Procedimiento de transferencia de genes por medio de retrotransposones.
KR100252547B1 (ko) 1991-09-05 2000-09-01 프레드 마리얀스키 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달
JPH07507794A (ja) 1992-06-17 1995-08-31 アドバンスド・マグネティクス・インク アラビノガラクタン誘導体及びその使用
US6225121B1 (en) 1992-09-14 2001-05-01 Institute Of Molecular Biology And Biotechnology/Forth Eukaryotic transposable element
US5589362A (en) 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
AU7321294A (en) 1993-06-30 1995-01-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The Transformed eukaryotic cells, and transposon-based transformation vectors
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
FR2736066B1 (fr) 1995-06-30 1998-11-20 Ajinomoto Kk Procede d'amplification d'un gene par transposon artificiel, bacterie coryneforme obtenue par ce procede et procede de production d'un acide amine a l'aide de cette bacterie
AU7665396A (en) 1995-10-27 1997-05-15 Trustees Of The University Of Pennsylvania, The Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
EP0885307A1 (de) 1996-02-09 1998-12-23 Vereniging Het Nederlands Kanker Instituut Vektoren und verfahren für die herstellung von zellen, die zusätzliches genetisches material in ihrem genom integriert enthalten.
US5948681A (en) * 1996-08-14 1999-09-07 Children's Hospital Of Philadelphia Non-viral vehicles for use in gene transfer
US5928888A (en) * 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
WO1998024479A1 (en) 1996-12-02 1998-06-11 Cell Genesys, Inc. Adeno-associated viral vector-mediated delivery of dna to cells of the liver
DK0973928T3 (da) * 1997-03-11 2010-08-09 Univ Minnesota DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
WO1998056903A1 (en) 1997-06-13 1998-12-17 President And Fellows Of Harvard College Methods and uses for transposon-based gene targeting
WO1999025817A2 (en) 1997-11-13 1999-05-27 Regents Of The University Of Minnesota Tc1-based transposon vectors
CN1333678A (zh) 1998-05-20 2002-01-30 表达遗传学公司 定向肝细胞的聚乙二醇接枝的聚－l－赖氨酸的聚合基因载体
US6303362B1 (en) 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
JP2002543792A (ja) 1999-05-11 2002-12-24 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ベクターによるトランスポゾン配列の供給及び組込み
WO2001030965A2 (en) 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
AU2001265756A1 (en) 2000-04-27 2001-11-07 Max-Delbruck-Centrum Fur Molekulare Medizin Sleeping beauty, a transposon vector with a broad host range for the genetic transfprmation in vertebrates
EP1286699A2 (de) 2000-05-19 2003-03-05 Regents Of The University Of Minnesota Zusammenzsetzungen fur arzneimittelabgabe zur zellen
WO2001091802A1 (en) 2000-05-30 2001-12-06 Baylor College Of Medicine Chimeric viral vectors for gene therapy
JP2004267001A (ja) 2000-08-16 2004-09-30 Kansai Tlo Kk トランスジェニック哺乳動物及びその作製方法並びにこれを用いた遺伝子機能の解明方法
US7985739B2 (en) * 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same

Also Published As

Publication number Publication date
US20020016975A1 (en) 2002-02-07
US20030124668A1 (en) 2003-07-03
WO1998040510A1 (en) 1998-09-17
US7148203B2 (en) 2006-12-12
EP0973928A1 (de) 2000-01-26
DE69841648D1 (de) 2010-06-17
DK0973928T3 (da) 2010-08-09
US6489458B2 (en) 2002-12-03
CA2280997C (en) 2013-05-28
AU6456998A (en) 1998-09-29
EP0973928B1 (de) 2010-05-05
AU745049B2 (en) 2002-03-07
JP2002511741A (ja) 2002-04-16
CA2280997A1 (en) 1998-09-17
KR20000076157A (ko) 2000-12-26
JP2008271981A (ja) 2008-11-13

Similar Documents

Publication Publication Date Title
DE69841648D1 (de) Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle
ATE239090T1 (de) Methode zum generieren von einzelsträngigen dna molekülen
AU4438099A (en) Nucleotide analogues with 3'-pro-fluorescent fluorophores in nucleic acid sequence analysis
BR9510003A (pt) Moléculas de dna enzimático
DE69636866D1 (en) Reverse "two-hybrid"-systeme
NZ333128A (en) Engineered human DNase I with DNA hydrolytic activity at least 50 percent greater than native human DNase I
EP1034302A4 (de) De novo oder "universaler" sequenzierungs-array
BR9407712A (pt) Métodos e composiçoes para sequenciamento eficaz de ácidos nuclêicos
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
ATE364718T1 (de) Verfahren zur vervielfältigung von nukleinsäure
ATE269908T1 (de) Methode zur sequenzierung von nukleinsäuren
AU3199699A (en) Modified nucleotides and methods useful for nucleic acid sequencing
FI971611L (fi) DNA-polymeraaseja joilla on modifioitu nukleotidisitoutumiskohta DNA-sekvensointia varten
ES2130177T3 (es) Tratamiento de poblaciones de celulas.
BR9809433A (pt) Moléculas de dna enzimáticas
BR9811592A (pt) Oxidase de citocinina
DE69936919D1 (en) Fy7 polymerase
ATE226216T1 (de) Netrinrezeptoren
DE69927795D1 (en) Temperaturstabile dna polymerase aus thermoanaerobacter thermohydrosulfuricus
EP1452540A3 (de) Molekularsequenz von Schweineretrovirus sowie Anwendungsverfahren
WO1998054313A3 (en) Dna methyltransferase genomic sequences and antisense oligonucleotides
DE59608651D1 (de) Verfahren zur sequenzierung durch oligomerhybridisierung
ATE348158T1 (de) Neuartiges collectin
ATE172470T1 (de) Für den interleukin-9-rezeptor kodierende nukleinsäuresequenzen bzw. dafür komplementäre nuleinsäuresequenzen
IT8119759A0 (it) Umano, dna e plasmidi che polipeptide prodotto codificano per questa sequenza, microbiologicamente con la sequenza microorganismi che contengono di aminoacidi dell'interferone queste informazioni genetiche e processo per la loro preparazione.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties